Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression

Aristide Merola, Yuki Mukai, Tjerk Bueters, Paulette Ceesay, Nicole Dupre, Christine Furtek, Gerard Sanacora, Michael E. Thase, Steven D. Targum, Sean M. Smith, Michael F. Egan

Open source

DOI: 10.1097/jcp.0000000000002171
Published: 2026-03-19
Container: Journal of Clinical Psychopharmacology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/jcp.0000000000002171,
  title = {Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression},
  author = {Aristide Merola and Yuki Mukai and Tjerk Bueters and Paulette Ceesay and Nicole Dupre and Christine Furtek and Gerard Sanacora and Michael E. Thase and Steven D. Targum and Sean M. Smith and Michael F. Egan},
  year = {2026},
  journal = {Journal of Clinical Psychopharmacology},
  doi = {10.1097/jcp.0000000000002171},
  url = {https://doi.org/10.1097/jcp.0000000000002171}
}

RIS

TY  - JOUR
TI  - Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression
AU  - Aristide Merola
AU  - Yuki Mukai
AU  - Tjerk Bueters
AU  - Paulette Ceesay
AU  - Nicole Dupre
AU  - Christine Furtek
AU  - Gerard Sanacora
AU  - Michael E. Thase
AU  - Steven D. Targum
AU  - Sean M. Smith
AU  - Michael F. Egan
PY  - 2026
JO  - Journal of Clinical Psychopharmacology
DO  - 10.1097/jcp.0000000000002171
UR  - https://doi.org/10.1097/jcp.0000000000002171
ER  -

APA

Merola, A., Mukai, Y., Bueters, T., Ceesay, P., Dupre, N., Furtek, C., Sanacora, G., Thase, M. E., Targum, S. D., Smith, S. M., & Egan, M. F. (2026). Phase 2 Clinical Trial of MK-1942, a Negative Allosteric Modulator of Metabotropic Glutamate Receptor 2, for Treatment-Resistant Depression. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/jcp.0000000000002171

Source records

crossref · retrieved 2026-11-11T01:50:09.149Z